NCT/Study#
NCT05691478 /
COG-AOST2032
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase II/III
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
